Physician profile
Richard Gordon
NPI 1558367490
$3,952.35
in general payments reported to CMS, 2019-2025
28 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $220 · 2021: $286 · 2022: $270 · 2023: $1,156 · 2024: $651 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,192.02 | 2021-2025 | Gallant, Jot Dx, Assurity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.22 | 2019-2022 | |
| Amgen INC. | $403.13 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $338.96 | 2019-2024 | |
| Akcea Therapeutics, INC. | $250.27 | 2019 | |
| Impulse Dynamics (USA) INC. | $166.98 | 2023 | Optimizer |
| Edwards Lifesciences Corporation | $140.10 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $136.30 | 2019-2021 | |
| Pfizer INC. | $134.77 | 2019-2024 | |
| Chiesi USA, INC. | $121.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $115.27 | 2019-2023 | Farxiga |
| Medtronic Vascular, INC. | $93.71 | 2019 | |
| Becton, Dickinson and Company | $62.29 | 2025 | |
| Cordis US Corp. | $38.96 | 2025 | Mynx Control Venous |
| Actelion Pharmaceuticals US, INC. | $38.84 | 2023-2024 | Opsumit, Uptravi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $37.58 | 2019-2021 | |
| Boston Scientific Corporation | $28.17 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $27.55 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $25.81 | 2024 | |
| Atricure, INC. | $25.04 | 2020 | |
| Bridgebio Pharma, INC. | $22.03 | 2025 | Attruby |
| Philips North America LLC | $21.11 | 2020 | |
| Circa Scientific, INC. | $20.63 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.78 | 2022-2025 | Lifevest |
| Medtronic, INC. | $14.86 | 2022 | |
| Cmp Pharma, INC. | $14.18 | 2024 | Liqrev, Norliqva, Tadliq |
| Novo Nordisk INC | $13.45 | 2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.